This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhatia, S. Articles by Giudice, L. C. Search for Related Content PubMed PubMed Citation Articles by Bhatia, S. Articles by Giudice, L. C.

A Longitudinal Analysis of Maternal Serum Insulin-Like Growth Factor I (IGF-I) and Total and Nonphosphorylated IGF-Binding Protein-1 in Human Pregnancies Complicated by Intrauterine Growth Restriction

Departments of Gynecology and Obstetrics (S.B., G.H.F., G.C., R.L.B., M.D., Y.E.-S., L.C.G.) and Pediatrics (D.M.W.), Stanford University Medical Center, Stanford, California 94305; Diagostics Systems Laboratories, Inc. (S.E.G.), Webster, Texas 77598; and Children’s Hospital Oakland (S.B.), Oakland, California 94609

Address all correspondence and requests for reprints to: Linda C. Giudice, Ph.D., M.D., Department of Gynecology and Obstetrics, Section of Reproductive Endocrinology and Infertility, Center for Research on Women’s Health and Reproductive Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Room HH 333, MC 5317, Stanford, California 94305-5317. E-mail: . giudice{at}stanford.edu

Abstract

In cord blood and late gestation maternal serum, IGF-I is positively correlated with birth weight, whereas IGF-binding protein-1 (IGFBP-1) is inversely correlated with birth weight. Our goal was to determine whether maternal serum or amniotic fluid concentrations of IGF-I, IGFBP-1, or nonphosphorylated IGFBP-1 (npIGFBP-1) in early gestation predict later fetal growth abnormalities. Maternal serum was collected prospectively across gestation (5–40 wk) from 749 pregnant subjects. Amniotic fluid was collected after amniocentesis during wk 15–26 from 207 subjects. We compared median serum concentrations of IGF-I, IGFBP-1, and npIGFBP-1 in 38 subjects who delivered growth-restricted infants with the control group of 236 subjects with normal weight infants for each gestational age grouping, wk 5–12, 13–23, and 24–34. In the control group median IGF-I concentrations were 14.8, 11, and 15.6 nmol/liter for wk 5–12, 13–23, and 24–34, respectively, compared with 13.7, 14.3, and 10.6 nmol/liter in the intrauterine growth restriction (IUGR) group. Median IGFBP-1 concentrations were 8.5, 30.4, and 24.4 nmol/liter, respectively, in controls, compared with 11.4, 28.6, and 25.5 nmol/liter in the IUGR group. Median npIGFBP-1 concentrations were 6.9, 22, and 17.4 nmol/liter, respectively, in controls, compared with 5.0, 32.1, and 24.2 nmol/liter in the IUGR group. In the control group the median amniotic fluid IGFBP-1 level was 13,160 nmol/liter, and the median npIGFBP-1 level was 15,970 nmol/liter; in the IUGR group these levels were 13,440 and 18,440 nmol/liter, respectively. No clinically useful differences were found between the IUGR and control groups. Our results do not support the use of maternal serum IGF-I or IGFBP-1 or amniotic fluid IGFBP-1 or npIGFBP-1 early in gestation to predict later fetal growth restriction.

This article has been cited by other articles:

				V. E. Murphy, R. Smith, W. B. Giles, and V. L. Clifton Endocrine Regulation of Human Fetal Growth: The Role of the Mother, Placenta, and Fetus Endocr. Rev., April 1, 2006; 27(2): 141 - 169. [Abstract] [Full Text] [PDF]

				D. K. Tisi, J. J. Emard, and K. G. Koski Total Protein Concentration in Human Amniotic Fluid Is Negatively Associated with Infant Birth Weight J. Nutr., July 1, 2004; 134(7): 1754 - 1758. [Abstract] [Full Text]